Faeth Therapeutics, Inc. FTH
19.99 USD +0.34 (+1.73%)
At closeNov 4, 2026, 5:55 PM EST
19.90 -0.09 -0.45%
After hours · Nov 4, 5:55 PM ET
19.08 Day range 20.44
7.45 52-week range 42.14
- YTD
- +87.35%
- 1 year
- +130.30%
News
benzinga.com Guggenheim Maintains Buy on Faeth Therapeutics, Lowers Price Target to $69 Guggenheim analyst Michael Schmidt maintains Faeth Therapeutics (NASDAQ:FTH) with a Buy and lowers the price target from $70 to $69.
benzinga.com Faeth Therapeutics Q3 EPS $(0.79) Misses $(0.71) Estimate Faeth Therapeutics (NASDAQ:FTH) reported quarterly losses of $(0.79) per share which missed the analyst consensus estimate of $(0.71) by 11.27 percent. This is a 78.18 percent increase over losses of…
businesswire.com Faeth Therapeutics Reports Third Quarter 2026 Financial Results and Operational Updates AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today…
businesswire.com Faeth Appoints Adam Schayowitz, Ph.D., MBA, Head of Research and Development at Zymeworks, to Board of Directors AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today…- benzinga.com BTIG Reiterates Buy on Faeth Therapeutics, Maintains $55 Price Target BTIG analyst Jeet Mukherjee reiterates Faeth Therapeutics (NASDAQ:FTH) with a Buy and maintains $55 price target.
businesswire.com Faeth Presents Updated Preclinical Data at ESMO, including First-Ever Head-to-Head Characterization of PIKTOR against Gedatolisib AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today…
businesswire.com Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced that the Compensation Committee of Faeth's Board of Directors granted three new employees options to purchase an…
businesswire.com Faeth to Present Preclinical Data on PIKTOR in HR+/HER2- Breast Cancer Models at ESMO 2026 AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today…
defenseworld.net Sensei Biotherapeutics (NASDAQ:FTH) Shares Gap Up – Here’s What Happened Sensei Biotherapeutics, Inc. (NASDAQ: FTH - Get Free Report)'s share price gapped up prior to trading on Friday. The stock had previously closed at $20.00, but opened at $21.00. Sensei…
benzinga.com William Blair Initiates Coverage On Faeth Therapeutics with Outperform Rating William Blair analyst Alethia Young initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Outperform rating.
gurufocus.com Faeth Therapeutics Appoints Karen Vousden, Ph.D., to Board of Directors Faeth Therapeutics, Inc. (Nasdaq: FTH), a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition o
businesswire.com Faeth Therapeutics Appoints Karen Vousden, Ph.D., to Board of Directors AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics, Inc. (Nasdaq: FTH), a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of…
benzinga.com Guggenheim Initiates Coverage On Faeth Therapeutics with Buy Rating, Announces Price Target of $70 Guggenheim analyst Brad Canino initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Buy rating and announces Price Target of $70.- benzinga.com LUCID CAPITAL MARKETS Initiates Coverage On Faeth Therapeutics with Buy Rating, Announces Price Target of $59 LUCID CAPITAL MARKETS analyst Dev Prasad initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Buy rating and announces Price Target of $59.
businesswire.com Faeth Therapeutics to Host Virtual KOL Event on Multi-Nodal Inhibition for the Treatment of Endometrial Cancer on October 6, 2026 AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today…
zacks.com What Makes Faeth Therapeutics, Inc. (FTH) a Strong Momentum Stock: Buy Now? Does Faeth Therapeutics, Inc. (FTH) have what it takes to be a top stock pick for momentum investors? Let's find out.
gurufocus.com Faeth Therapeutics to Participate in Upcoming September Investor Conferences [url="]Faeth Therapeutics[/url] (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program
businesswire.com Faeth Therapeutics to Participate in Upcoming September Investor Conferences AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today…
businesswire.com Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced that the Compensation Committee of Faeth's Board of Directors granted three new employees options to purchase an…
zacks.com Wall Street Analysts Predict a 72.22% Upside in Faeth Therapeutics, Inc. (FTH): Here's What You Should Know The mean of analysts' price targets for Faeth Therapeutics, Inc. (FTH) points to a 72.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong…
benzinga.com This Nvidia Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday Top Wall Street analysts changed outlook on top names. See all changes on analyst ratings page. AVGO receives Outperform rating with $455 PT.- benzinga.com Needham Initiates Coverage On Faeth Therapeutics with Buy Rating, Announces Price Target of $56 Needham analyst Gil Blum initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Buy rating and announces Price Target of $56.
- benzinga.com Faeth Therapeutics Says FDA Grants Fast Track Designation To Combination Of Sapanisertib And Serabelisib With Paclitaxel For Treatment Of Patients With Endometrial Cancer — Fast Track designation applies to sapanisertib and serabelisib (PIKTOR) in combination with paclitaxel for the treatment of patients with advanced or recurrent endometrial cancer whose tumors…
businesswire.com Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today…
businesswire.com Faeth Therapeutics Strengthens Executive Team with Senior Leadership Appointments AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced the appointments of Deepak Tiwari as Senior Vice President, Technical Operations, and Matt Biegler as Senior…
benzinga.com HC Wainwright & Co. Reiterates Buy on Faeth Therapeutics, Maintains $60 Price Target HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Faeth Therapeutics (NASDAQ:FTH) with a Buy and maintains $60 price target.
businesswire.com Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced that the Compensation Committee of Faeth's Board of Directors granted two new employees options to purchase an…
gurufocus.com Faeth Therapeutics to Present PK/PD Modeling That Informed PIKTOR Dose Selection in Ongoing FTH-PIK-201 Trial at Upcoming Scientific Conference Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing PIKTOR, an investigational all-oral, multi-node inhibitor of the PI3K/AKT/mTOR pa- benzinga.com Faeth Therapeutics To Present Translational Data And Pharmacokinetic/Pharmacodynamic Analysis For PIKTOR, Oral Combination Of Serabelisib And Sapanisertib, At 2026 Summit For STOP Cancer — The data will be presented at the 2026 Summit for Novel Therapeutics in Oncology and Precision Medicine in Cancer conference on August 8— These data collectively informed PIKTOR dose selection in…
businesswire.com Faeth Therapeutics to Present PK/PD Modeling That Informed PIKTOR Dose Selection in Ongoing FTH-PIK-201 Trial at Upcoming Scientific Conference AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing PIKTOR, an investigational all-oral, multi-node inhibitor of the PI3K/AKT/mTOR pathway,…- benzinga.com Faeth Therapeutics Q2 EPS $(2.84) Beats $(3.29) Estimate Faeth Therapeutics (NASDAQ:FTH) reported quarterly losses of $(2.84) per share which beat the analyst consensus estimate of $(3.29) by 13.68 percent. This is a 27.37 percent increase over losses of…
businesswire.com Faeth Therapeutics Reports Second Quarter 2026 Financial Results and Operational Updates AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing PIKTOR, an investigational all-oral, multi-node inhibitor of the PI3K/AKT/mTOR pathway,…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock increased by 121.2% to $6.99 during Monday's pre-market session. The market value of their outstanding shares is at $2.0 million. Supernus…
benzinga.com This Faeth Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday Wall Street analysts changed outlook on top names. Check ratings page for upgrades, downgrades, initiations. See other analysts' views on HTFL, SKYH, FTH.
benzinga.com This Plexus Analyst Turns Bullish; Here Are Top 4 Upgrades For Friday Top Wall Street analysts upgraded IP, AXTI, REPL, and PLXS stocks with higher price targets. See what other analysts think about these stocks.
benzinga.com Raymond James Initiates Coverage On Faeth Therapeutics with Outperform Rating, Announces Price Target of $56 Raymond James analyst Sean McCutcheon initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Outperform rating and announces Price Target of $56.
benzinga.com This Crowdstrike Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday Top Wall Street analysts changed outlook on top names. See all rating changes on analyst ratings page. Analysts have positive views on FTH stock.- benzinga.com Oppenheimer Initiates Coverage On Faeth Therapeutics with Outperform Rating, Announces Price Target of $60 Oppenheimer analyst Jay Olson initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Outperform rating and announces Price Target of $60.
- benzinga.com Citizens Initiates Coverage On Faeth Therapeutics with Market Outperform Rating, Announces Price Target of $51 Citizens analyst Silvan Turkcan initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Market Outperform rating and announces Price Target of $51.
- benzinga.com BTIG Reiterates Buy on Faeth Therapeutics, Maintains $55 Price Target BTIG analyst Jeet Mukherjee reiterates Faeth Therapeutics (NASDAQ:FTH) with a Buy and maintains $55 price target.
benzinga.com This Robinhood Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday Top analysts changed outlook on top names. For all changes, see analyst ratings page. See how analysts view HOOD, FXNC, NU, FTH, FRST.- benzinga.com Baird Initiates Coverage On Faeth Therapeutics with Outperform Rating, Announces Price Target of $57 Baird analyst Jack Allen initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Outperform rating and announces Price Target of $57.
benzinga.com This Principal Financial Group Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday Top Wall Street analysts changed outlook on top names. View all changes on analyst ratings page. See what analysts think of these stocks.
benzinga.com This IBM Analyst Turns Bullish; Here Are Top 3 Upgrades For Tuesday Top Wall Street analysts changed outlook on top names. Piper Sandler upgraded SNPS, JP Morgan upgraded IBM,. See analyst ratings.
benzinga.com Backblaze, Infleqtion, Zeta Global And Other Big Stocks Moving Higher On Tuesday Dow Jones index fell 200+ points on Monday. Backblaze Inc rose 30.4% after $335M data storage deal with CoreWeave Inc. Other stocks also gained.
benzinga.com This Insulet Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday Wall Street analysts changed outlook on top names, including MCRB, SAFX. See analyst ratings page for full coverage.
benzinga.com This Apple Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Monday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings…
benzinga.com This Credo Technology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Top analysts changed ratings on top stocks, including Conexeu, CRDO, AGMB, SPCX, and FTH. See what analysts say about buying CRDO stock.
benzinga.com HC Wainwright & Co. Initiates Coverage On Faeth Therapeutics with Buy Rating, Announces Price Target of $60 HC Wainwright & Co. analyst Patrick R. Trucchio initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Buy rating and announces Price Target of $60.